Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update
Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platformMINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwideIn July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good…